On September 1, 2026, the FDA published a coordinated set of warning letters targeting five online peptide vendors. The sweep signals that the agency is shifting from case-by-case enforcement to sector-wide scrutiny — and that a "research use only" disclaimer is no longer a regulatory shield. Here is what the letters actually say, which vendors and products were named, and what it means for labs sourcing peptides today.
FDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar Market
An FDA advisory panel's split vote on peptide compounding sent Hims & Hers Health shares swinging Thursday, as Wall Street analysts weighed a potential multi-billion dollar telehealth opportunity against lingering safety concerns raised by the agency's own scientists.
Wall Street Reacts to the FDA's Split Decision
The FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend BPC-157, KPV and TB-500 for the agency's 503A Bulks List, while MOTS-C passed on a narrower 7-5-2 tally. The divided votes broke with FDA staff scientists, who had recommended against all seven peptides under review, citing weak human evidence, unclear formulations and unresolved safety concerns. The vote is only an advisory recommendation, not a final approval, and the FDA still has to make its own determination.
Why Hims & Hers Is at the Center of the Story
Hims & Hers acquired a California peptide manufacturing facility in early 2025 as part of its push into metabolic health, recovery and preventive care, positioning the company to benefit if these compounds gain a clearer regulatory pathway. Shares jumped more than 10% intraday Thursday following the initial BPC-157 vote before paring gains to close up roughly 3% at $32.74.
Analysts Size Up a Multi-Billion Dollar Opportunity
Leerink Partners called the outcome a "positive catalyst" for Hims, estimating the peptides under review could create a $2.2 billion annual telehealth market, with Hims potentially capturing about 20% of that opportunity. Still, Leerink maintained a Market Perform rating and $25 price target on the stock, citing uncertainty around Hims' ability to build and scale a new peptide platform.
What Testimony From Hims's Chief Medical Officer Revealed
Hims & Hers Chief Medical Officer Dr. Anant Vinjamoori testified before the committee this week, highlighting consumer demand for safer access to peptides that are currently sold through unregulated channels. The committee met again Friday to consider the remaining peptides under review, including Emideltide, Semax and Epitalon.
Frequently Asked Questions
What This Means for Kynetide Customers
Whether or not this vote leads to a formal rule change, it underscores the same divide we see across the peptide research space: enthusiasm for these compounds is racing ahead of regulatory clarity. That is exactly why Kynetide sells strictly for laboratory and research use, with a third-party Certificate of Analysis on every batch so researchers know precisely what they are working with. As this market grows more crowded, verified purity and transparent sourcing matter more, not less.










